$ICLR

Clerkin Nigel Bernard John sold $372K of ICLR

Clerkin Nigel Bernard John (Chief Financial Officer) sold 2,267 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.37M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · Clerkin Nigel Bernard John
Published Aug 12, 2026, 8:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

Insider selling can be interpreted as mild negative sentiment, but without accompanying guidance, earnings, or operational news, it is unlikely to drive sustained repricing.

02

Market read

Traders may note the CFO’s sale as a sentiment datapoint, but the filing alone does not provide a new fundamental catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on compensation timing, tax obligations, or prior trading patterns.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after 2026-08-11 sale

Background

This is an SEC Form 4 insider transaction disclosure for ICON PLC, reported by the CFO.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC CFO Clerkin Nigel Bernard John sold $372,444 of ICLR shares via open-market transactions on 2026-08-11.

Expected impact

Likely limited, short-lived impact unless paired with other negative disclosures.

Evidence & confidence

Form 4 shows an open-market sale by the CFO with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operational or financial catalyst.

Market effects

No sector-level implications; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale may be driven by diversification, taxes, or pre-planned liquidity needs rather than a bearish view on ICON’s prospects.

Key entities

  • ICON PLC

    Subject of the Form 4 insider sale disclosure.

  • Clerkin Nigel Bernard John

    Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.